DK2371818T3 - Hydroxybenzoatsalte af metanikotinforbindelser - Google Patents

Hydroxybenzoatsalte af metanikotinforbindelser

Info

Publication number: DK2371818T3
Authority: DK; Denmark
Prior art keywords: methanicotine; compounds; hydroxybenzoate salts; hydroxybenzoate; salts
Prior art date: 2004-11-10

Application number

DK11002581.4T

Other languages

English (en)

Inventor

Julio A Munoz

John Genus

James R Moore

Original Assignee

Targacept Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-11-10

Filing date

2005-11-09

Publication date

2013-03-25

2005-11-09 Application filed by Targacept Inc filed Critical Targacept Inc

2013-03-25 Application granted granted Critical

2013-03-25 Publication of DK2371818T3 publication Critical patent/DK2371818T3/da

Links

150000001875 compounds Chemical class 0.000 title 1
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Psychology (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Cosmetics (AREA)

DK11002581.4T 2004-11-10 2005-11-09 Hydroxybenzoatsalte af metanikotinforbindelser DK2371818T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US62675104P	2004-11-10	2004-11-10
EP05819967.0A EP1814852B1 (en)	2004-11-10	2005-11-09	Hydroxybenzoate salts of metanicotine compounds

Publications (1)

Publication Number	Publication Date
DK2371818T3 true DK2371818T3 (da)	2013-03-25

Family

ID=36168607

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK11002581.4T DK2371818T3 (da)	2004-11-10	2005-11-09	Hydroxybenzoatsalte af metanikotinforbindelser

Country Status (26)

Country	Link
US (2)	US20060122238A1 (da)
EP (3)	EP2371818B1 (da)
JP (3)	JP4447038B2 (da)
KR (1)	KR101268890B1 (da)
CN (3)	CN102643228A (da)
AU (2)	AU2005304526B2 (da)
BR (1)	BRPI0517621A (da)
CA (3)	CA2584586A1 (da)
CY (1)	CY1113542T1 (da)
DK (1)	DK2371818T3 (da)
ES (1)	ES2404506T3 (da)
HR (1)	HRP20130215T1 (da)
IL (2)	IL182573A (da)
ME (1)	ME01503B (da)
MX (1)	MX2007005710A (da)
NO (1)	NO20072160L (da)
NZ (1)	NZ554689A (da)
PL (1)	PL2371818T3 (da)
PT (1)	PT2371818E (da)
RS (1)	RS52681B (da)
RU (1)	RU2409566C2 (da)
SG (1)	SG157379A1 (da)
SI (1)	SI2371818T1 (da)
UA (1)	UA88792C2 (da)
WO (2)	WO2006053039A2 (da)
ZA (2)	ZA200703759B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7459469B2 (en) *	2004-11-10	2008-12-02	Targacept, Inc.	Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) *	2004-11-10	2009-11-25	Таргасепт, Інк.	Гидроксибензоатные соли метаникотиновых соединений
WO2007055928A1 (en) *	2005-11-03	2007-05-18	Targacept, Inc.	5-membered ring metanicotine analogs
EP2021325A2 (en)	2006-05-09	2009-02-11	AstraZeneca AB	Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
TWI389889B (zh)	2006-05-09	2013-03-21	Targacept Inc	（２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
TW200829244A (en) *	2006-09-15	2008-07-16	Astrazeneca Ab	Therapeutic combinations 482
EP2112923A1 (en) *	2007-01-22	2009-11-04	Targacept Inc.	Intranasal, buccal, and sublingual administration of metanicotine analogs
ES2594867T3 (es)	2007-03-09	2016-12-23	Alexza Pharmaceuticals, Inc.	Unidad de calentamiento para usar en un dispositivo de administración de fármaco
WO2009018367A2 (en) *	2007-07-31	2009-02-05	Targacept, Inc.	Novel salt forms of (2s)-(4e)-n-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine
CN101772343A (zh) *	2007-07-31	2010-07-07	塔格赛普有限公司	(2s)-(4e)-n-甲基-5-(3-(5-异丙氧基吡啶)基)-4-戊烯-2-胺的经皮给药
CN101774922B (zh) *	2010-01-29	2012-12-26	浙江大学	2,3-二羟基苯甲酸酯类化合物及制备和应用
BR112012029326A2 (pt) *	2010-05-20	2017-08-08	Astrazeneca Ab	processo para a preparação de animais olefínicas substituídas por arila
CA3208137A1 (en)	2013-05-06	2014-11-13	Juul Labs, Inc.	Nicotine salt formulations for aerosol devices and methods thereof
CN111249584B (zh) *	2013-07-11	2022-04-26	艾利斯达医药品公司	与间水杨酸形成的烟碱盐
CN119606056A (zh)	2013-12-05	2025-03-14	尤尔实验室有限公司	用于气雾剂装置的尼古丁液体制剂及其方法
US9896429B2 (en)	2014-05-27	2018-02-20	R.J. Reynolds Tobacco Company	Nicotine salts, co-crystals, and salt co-crystal complexes
EP4603486A3 (en) *	2014-05-27	2025-10-15	R.J. Reynolds Tobacco Company	Nicotine salts, co-crystals, and salt co-crystal complexes
US10508096B2 (en)	2014-05-27	2019-12-17	R.J. Reynolds Tobacco Company	Nicotine salts, co-crystals, and salt co-crystal complexes
MX2020007997A (es)	2018-02-02	2020-12-03	Alexza Pharmaceuticals Inc	Dispositivo electrico de aerosol de condensacion.
CN113200967B (zh) *	2021-05-07	2022-05-24	中国人民解放军陆军军医大学	吲哚苯醌类化合物、其制备方法及其应用
CN113475740B (zh) *	2021-07-10	2022-10-21	深圳市真味生物科技有限公司	一种手性合成尼古丁的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4192946A (en)	1978-06-29	1980-03-11	Ciba-Geigy Corporation	Process for producing 3-hydroxy-5-halopyridines
DE3148651A1 (de) *	1981-12-09	1983-07-21	Henkel Kgaa	"haarfaerbemittel, enthaltend 5-halo-2,3-pyridindiole als kupplerkomponente"
US4582823A (en) *	1984-08-15	1986-04-15	Warner-Lambert Company	Method for treating schizophrenia and medicaments therefor
WO1989000158A1 (en)	1987-07-02	1989-01-12	Pfizer Inc.	Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
IT1226727B (it) *	1988-07-29	1991-02-05	Simes	Farmaci precursori della dopamina.
US4922901A (en) *	1988-09-08	1990-05-08	R. J. Reynolds Tobacco Company	Drug delivery articles utilizing electrical energy
EP0393781B1 (en) *	1989-04-20	1995-02-08	ZAMBON GROUP S.p.A.	Dopamine pro-drug
US5187166A (en) *	1990-07-31	1993-02-16	Nisshin Flour Milling Co., Ltd.	Azabicyclo derivatives and their use as antiemetics
WO1992012122A1 (en)	1990-12-27	1992-07-23	Abbott Laboratories	N-protected aminoalkylaldehydes
EP0516409B1 (en)	1991-05-30	1996-09-11	MITSUI TOATSU CHEMICALS, Inc.	Tetravinylpyrazine compound, method for preparing same and electroluminescent element and non-linear optical material using same
US5212188A (en)	1992-03-02	1993-05-18	R. J. Reynolds Tabacco Company	Method for treatment of neurodegenerative diseases
IL107184A (en)	1992-10-09	1997-08-14	Abbott Lab	Heterocyclic ether compounds that enhance cognitive function
US5852041A (en)	1993-04-07	1998-12-22	Sibia Neurosciences, Inc.	Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) *	1994-02-23	1997-07-14	Riace Ets	Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en)	1994-11-23	1996-05-29	Glaxo Inc	Quinazoline antagonists of alpha 1c adrenergic receptors
US5616707A (en) *	1995-01-06	1997-04-01	Crooks; Peter A.	Compounds which are useful for prevention and treatment of central nervous system disorders
US5597919A (en) *	1995-01-06	1997-01-28	Dull; Gary M.	Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en)	1995-01-06	1997-02-18	Smith; Carr J.	Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en)	1995-04-07	1996-12-17	Sibia Neurosciences, Inc.	Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en)	1995-05-17	1996-12-10	Bencherif; Merouane	Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en)	1995-06-07	2006-10-05	Abbott Lab	Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) *	1996-01-06	1997-04-01	Dull; Gary M.	(3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) *	1996-04-19	1998-05-25	Sanochemia Ltd	Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US20020052497A1 (en) *	2000-03-09	2002-05-02	Targacept, Inc.	Compounds capable of activating cholinergic receptors
US5663356A (en)	1996-04-23	1997-09-02	Ruecroft; Graham	Method for preparation of aryl substituted alefinic secondary amino compounds
ATE416164T1 (de)	1996-04-23	2008-12-15	Targacept Inc	Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungen
US5861423A (en)	1997-02-21	1999-01-19	Caldwell; William Scott	Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US5811442A (en) *	1997-02-21	1998-09-22	Bencherif; Merouane	Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
ES2172882T3 (es) *	1997-05-08	2002-10-01	Pfizer Prod Inc	Procedimientos y productos intermedios para la preparacion de derivados indazol sustituidos.
KR100607838B1 (ko)	1997-10-27	2006-08-04	뉴로서치 에이/에스	니코틴 작용성 아세틸콜린 수용체상의 콜린 작용성 리간드로서의 호모피페라진 유도체 및 이를 포함하는 약제학적 조성물
US6632823B1 (en) *	1997-12-22	2003-10-14	Merck & Co., Inc.	Substituted pyridine compounds useful as modulators of acetylcholine receptors
CA2709735A1 (en)	1998-06-16	1999-12-23	Targacept, Inc.	Aryl substituted olefinic amines and their use as cholinergic receptors agonists
US6232316B1 (en) *	1998-06-16	2001-05-15	Targacept, Inc.	Methods for treatment of CNS disorders
US6218383B1 (en)	1998-08-07	2001-04-17	Targacept, Inc.	Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6337351B1 (en) *	1998-10-22	2002-01-08	Targacept, Inc.	Pharmaceutical compositions and methods for use
GB9922271D0 (en) *	1999-09-21	1999-11-17	Zeneca Ltd	Formulation
US6506769B2 (en) *	1999-10-06	2003-01-14	Boehringer Ingelheim Pharmaceuticals, Inc.	Heterocyclic compounds useful as inhibitors of tyrosine kinases
WO2001078735A1 (en) *	2000-04-13	2001-10-25	Innovata Biomed Limited	Medicaments for treating respiratory disorders comprising formoterol and fluticasone
US6432954B1 (en) *	2000-07-14	2002-08-13	Targacept, Inc.	Pharmaceutical compositions and methods for use
US6743812B1 (en) *	2000-07-14	2004-06-01	Targacept, Inc.	Pharmaceutical compositions and methods for use
GB2381750A (en) *	2001-10-10	2003-05-14	Inspire Pharmaceuticals Inc	Treatment for enhancing joint lubrication
US20040044023A1 (en) *	2002-08-30	2004-03-04	Marc Cantillon	Compositions and methods for treating or preventing memory impairment
US20050203130A1 (en) *	2003-12-02	2005-09-15	Erik Buntinx	Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
UA88792C2 (ru) *	2004-11-10	2009-11-25	Таргасепт, Інк.	Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) *	2004-11-10	2008-12-02	Targacept, Inc.	Hydroxybenzoate salts of metanicotine compounds
TWI389889B (zh) *	2006-05-09	2013-03-21	Targacept Inc	（２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
TW200829244A (en) *	2006-09-15	2008-07-16	Astrazeneca Ab	Therapeutic combinations 482

2005
- 2005-09-11 UA UAA200706359A patent/UA88792C2/ru unknown
- 2005-11-09 RS RS20130081A patent/RS52681B/sr unknown
- 2005-11-09 SG SG200907438-6A patent/SG157379A1/en unknown
- 2005-11-09 CA CA002584586A patent/CA2584586A1/en not_active Abandoned
- 2005-11-09 CN CN2012100831307A patent/CN102643228A/zh active Pending
- 2005-11-09 DK DK11002581.4T patent/DK2371818T3/da active
- 2005-11-09 RU RU2007121697/04A patent/RU2409566C2/ru not_active IP Right Cessation
- 2005-11-09 ME MEP-2013-25A patent/ME01503B/me unknown
- 2005-11-09 MX MX2007005710A patent/MX2007005710A/es active IP Right Grant
- 2005-11-09 WO PCT/US2005/040588 patent/WO2006053039A2/en not_active Ceased
- 2005-11-09 SI SI200531683T patent/SI2371818T1/sl unknown
- 2005-11-09 PT PT110025814T patent/PT2371818E/pt unknown
- 2005-11-09 CA CA2793138A patent/CA2793138C/en not_active Expired - Fee Related
- 2005-11-09 AU AU2005304526A patent/AU2005304526B2/en not_active Ceased
- 2005-11-09 PL PL11002581T patent/PL2371818T3/pl unknown
- 2005-11-09 CN CNA2005800416139A patent/CN101068784A/zh active Pending
- 2005-11-09 NZ NZ554689A patent/NZ554689A/en not_active IP Right Cessation
- 2005-11-09 US US11/270,753 patent/US20060122238A1/en not_active Abandoned
- 2005-11-09 CN CNA2005800416143A patent/CN101068785A/zh active Pending
- 2005-11-09 BR BRPI0517621-2A patent/BRPI0517621A/pt not_active Application Discontinuation
- 2005-11-09 AU AU2005304575A patent/AU2005304575A1/en not_active Abandoned
- 2005-11-09 EP EP11002581A patent/EP2371818B1/en not_active Expired - Lifetime
- 2005-11-09 WO PCT/US2005/040650 patent/WO2006053082A2/en not_active Ceased
- 2005-11-09 JP JP2007540196A patent/JP4447038B2/ja not_active Expired - Fee Related
- 2005-11-09 ES ES11002581T patent/ES2404506T3/es not_active Expired - Lifetime
- 2005-11-09 EP EP05851465A patent/EP1814853A2/en not_active Withdrawn
- 2005-11-09 JP JP2007540192A patent/JP2008519766A/ja not_active Withdrawn
- 2005-11-09 KR KR1020077010149A patent/KR101268890B1/ko not_active Expired - Fee Related
- 2005-11-09 CA CA2584448A patent/CA2584448C/en not_active Expired - Fee Related
- 2005-11-09 EP EP05819967.0A patent/EP1814852B1/en not_active Expired - Lifetime
2007
- 2007-04-16 IL IL182573A patent/IL182573A/en not_active IP Right Cessation
- 2007-04-26 NO NO20072160A patent/NO20072160L/no not_active Application Discontinuation
- 2007-05-09 ZA ZA200703759A patent/ZA200703759B/xx unknown
2008
- 2008-06-19 US US12/142,471 patent/US20080249142A1/en not_active Abandoned
- 2008-11-14 JP JP2008291862A patent/JP4764911B2/ja not_active Expired - Fee Related
2009
- 2009-04-16 ZA ZA2009/02634A patent/ZA200902634B/en unknown
2012
- 2012-12-17 IL IL223681A patent/IL223681A0/en unknown
2013
- 2013-01-14 CY CY20131100038T patent/CY1113542T1/el unknown
- 2013-03-12 HR HRP20130215TT patent/HRP20130215T1/hr unknown

Also Published As

Publication number	Publication date
AU2005304526B2 (en)	2011-09-01
WO2006053082A2 (en)	2006-05-18
PT2371818E (pt)	2013-03-05
ME01503B (me)	2014-04-20
SI2371818T1 (sl)	2013-04-30
CA2584448A1 (en)	2006-05-18
WO2006053039A3 (en)	2006-12-07
CA2793138C (en)	2014-12-23
JP4764911B2 (ja)	2011-09-07
NO20072160L (no)	2007-06-06
EP2371818A1 (en)	2011-10-05
ZA200703759B (en)	2009-11-25
RS52681B (sr)	2013-06-28
US20080249142A1 (en)	2008-10-09
ES2404506T3 (es)	2013-05-28
CN102643228A (zh)	2012-08-22
AU2005304526A1 (en)	2006-05-18
JP2008519768A (ja)	2008-06-12
EP1814852A2 (en)	2007-08-08
EP1814853A2 (en)	2007-08-08
CY1113542T1 (el)	2016-06-22
KR20070083966A (ko)	2007-08-24
US20060122238A1 (en)	2006-06-08
SG157379A1 (en)	2009-12-29
WO2006053039A2 (en)	2006-05-18
PL2371818T3 (pl)	2013-05-31
RU2007121697A (ru)	2008-12-20
CA2584448C (en)	2013-05-07
MX2007005710A (es)	2007-07-09
WO2006053082A3 (en)	2006-10-19
IL182573A0 (en)	2007-07-24
EP2371818B1 (en)	2012-12-26
KR101268890B1 (ko)	2013-05-29
UA88792C2 (ru)	2009-11-25
JP4447038B2 (ja)	2010-04-07
JP2008519766A (ja)	2008-06-12
EP1814852B1 (en)	2016-01-20
HRP20130215T1 (hr)	2013-04-30
AU2005304575A1 (en)	2006-05-18
CN101068784A (zh)	2007-11-07
CA2793138A1 (en)	2006-05-18
BRPI0517621A (pt)	2008-10-14
ZA200902634B (en)	2011-12-28
IL223681A0 (en)	2013-02-03
CA2584586A1 (en)	2006-05-18
NZ554689A (en)	2009-12-24
CN101068785A (zh)	2007-11-07
JP2009108082A (ja)	2009-05-21
IL182573A (en)	2014-01-30
RU2409566C2 (ru)	2011-01-20

Publication	Publication Date	Title
DK1802579T3 (da)	2014-01-20	Derivater af 3-arylaminopyridin
DK1778618T3 (da)	2014-03-10	Syntese af triethylentetraminer
DK2377869T3 (da)	2014-04-14	Syntese af Bortezomib
IL223681A0 (en)	2013-02-03	Hydroxybenzoate salts of metanicotine compounds
DK1778672T3 (da)	2013-03-25	Krystallinsk form af en biphenylforbindelse
DK1951636T3 (da)	2014-01-27	Fremstilling af cementholdig plade
DK2111555T3 (da)	2013-09-02	Diagnosticering af præeklampsi
DK1963302T3 (da)	2013-04-02	Polymorfer af en C-MET/HGFR-inhibitor
DK1856050T3 (da)	2010-02-01	Krystallinske former af en biphenylforbindelse
DK1937071T3 (da)	2011-11-28	Krystallinske modifikationer af pyraclostrobin
DK2031948T3 (da)	2013-01-07	Bestemmelse af en komponents brugstid
DK2081675T3 (da)	2013-08-26	Syntese af biodiesel
DK1874766T3 (da)	2010-12-06	Krystallinsk form af en quinolinon-carboxamid-forbindelse
NO20070299L (no)	2007-03-26	Novel heterocyclic compounds
ATE404546T1 (de)	2008-08-15	Substituierte n-sulfonylaminobenzyl-2- phenoxyacetamidverbindungen
DK1763520T3 (da)	2009-02-09	Anvendelse af trisubstituerede benzopyranoner
DK1877403T3 (da)	2011-05-09	Mono-lysinsalte af azolforbindelser
DK1730109T3 (da)	2008-09-29	Syntese af pyrrol-2-carbonitriler
SE0400022D0 (sv)	2004-01-08	New compounds
SE0402103D0 (sv)	2004-08-30	Novel compounds
ATE384719T1 (de)	2008-02-15	Dioxazinyl-substituierte thienylsulfonylaminocarbonylverbindungen
DK1787450T3 (da)	2014-09-22	Udvælgelse af information
SE0400254D0 (sv)	2004-02-06	New compounds
SE0400044D0 (sv)	2004-01-12	New compounds
SE0401667D0 (sv)	2004-06-28	New compounds